Argenx is a biotech company transforming immunology and delivering medicines that help autoimmune patients get their lives back. The company is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, a first-in-class neonatal Fc receptor blocker approved for the treatment of gMG.
